Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Inflammatory Bowel Diseases

Free Subscription 20.04.2026 7 Aliment Pharmacol Ther 2 BMC Gastroenterol 3 Clin Gastroenterol Hepatol 1 Clin Res Hepatol Gastroenterol 3 Dig Dis Sci 1 Dis Colon Rectum 2 Gastroenterol Hepatol 1 Gastroenterology 7 Inflamm Bowel Dis 1 J Clin Gastroenterol 12 J Crohns Colitis 2 J Gastroenterol 1 Minerva Gastroenterol (Torino) 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. RIGGOTT C, Fairbrass KM, Guthrie EA, Black CJ, et al
   Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease-A Core Phenotype Beyond Inflammatory Activity. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70673.
   PubMed        
   
   
2. BERTIN L, Savarino EV
   Letter: Beyond the Mucosa-Strengthening the Case for Transmural Healing as a Monitoring Target in Crohn's Disease.
   Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70674.
   PubMed        
   
   
3. MURTHY SK
   Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply.
   Aliment Pharmacol Ther. 2026 Apr 16. doi: 10.1111/apt.70679.
   PubMed        
   
   
4. SINGH AK, Birda CL
   Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease-Expanding Strategies Beyond Double-Dose Recombinant Vaccination. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70687.
   PubMed        
   
   
5. WANG R, Cao D, Cui Z
   Editorial-Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70672.
   PubMed        
   
   
6. ARATARI A, Festa S
   Editorial: Beyond Resection-Rethinking Postoperative Management in Colonic Crohn's Disease.
   Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70680.
   PubMed        
   
   
7. FONS AB, Maljaars PWJ
   Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply.
   Aliment Pharmacol Ther. 2026 Apr 14. doi: 10.1111/apt.70681.
   PubMed        
   
   

   
   BMC Gastroenterol

8. ALSHATTI Y, Alshammari S, Alenezi M, Alqattan A, et al
   Comparison of methylene blue dye-based chromoendoscopy and Fujifilm virtual chromoendoscopy (blue light imaging and linked color imaging) for dysplasia detection in inflammatory bowel disease: a prospective single-center randomized study.
   BMC Gastroenterol. 2026 Apr 14. doi: 10.1186/s12876-026-04828.
   PubMed        
   
   
9. ZHU N, Wang M, Wang M, Ren J, et al
   Bioinformatic validation of LCN2 as a common hub gene for ferroptosis, pyroptosis and necroptosis in ulcerative colitis.
   BMC Gastroenterol. 2026 Apr 11. doi: 10.1186/s12876-026-04801.
   PubMed        
   
   

   
   Clin Gastroenterol Hepatol

10. MARK-CHRISTENSEN A, Kristiansen EB, Laurberg S, Erichsen R, et al
    Decreasing primary resection rates for Crohn's disease but unchanged re-resection rates: A nationwide Danish population-based cohort study from 1997 to 2021.
    Clin Gastroenterol Hepatol. 2026 Apr 9:S1542-3565(26)00246.
    PubMed         Abstract available
    
    
11. PALMELA C, Reves J, Frias-Gomes C, Morao B, et al
    Use of Intestinal Ultrasound in a Tight monitoring approach in Crohn's disease: a multicentre prospective study.
    Clin Gastroenterol Hepatol. 2026 Apr 15:S1542-3565(26)00279.
    PubMed         Abstract available
    
    
12. AHUJA D, Park SK, Qi Y, Patel SB, et al
    Treatment and Outcomes of Crohn's Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007-23.
    Clin Gastroenterol Hepatol. 2026 Apr 15:S1542-3565(26)00280.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

13. WEI Q, Guan D, Fang Y, Guo J, et al
    Can peripheral blood eosinophils predict primary non-response to Infliximab therapy in pediatric Crohn's disease?
    Clin Res Hepatol Gastroenterol. 2026;50:102829.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

14. KAI N, Xiaoyan W
    A Microscopic Lens for Macroscopic Decisions in the "Non-lifting Sign" of Crohn's Disease.
    Dig Dis Sci. 2026 Apr 10. doi: 10.1007/s10620-026-09875.
    PubMed        
    
    
15. GARDEZI SAA, Iqbal MJ, Ulhaq S, Albustanji Q, et al
    Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Dig Dis Sci. 2026 Apr 13. doi: 10.1007/s10620-026-09887.
    PubMed         Abstract available
    
    
16. GOYAL A, Syal G, Fleshner P, Gu P, et al
    Malignancy in Long-Standing Perianal Fistulizing Crohn's Disease: Too Little, Too Late.
    Dig Dis Sci. 2026 Apr 13. doi: 10.1007/s10620-026-09882.
    PubMed         Abstract available
    
    

    
    Dis Colon Rectum

17. ALON G, Holubar S
    Ulcerative Colitis-Associated Neoplasia.
    Dis Colon Rectum. 2026 Apr 10. doi: 10.1097/DCR.0000000000004232.
    PubMed         Abstract available
    
    

    
    Gastroenterol Hepatol

18. ARRIERO VG, Moya MC, de Lucas Tellez de Meneses R, Partida IG, et al
    Mental Health and quality of Life in Inflammatory Bowel disease: Cross-sectional Study on its Impact.
    Gastroenterol Hepatol. 2026 Apr 14:502763. doi: 10.1016/j.gastrohep.2026.502763.
    PubMed         Abstract available
    
    
19. VILLAMIL MPG, Bein MV, Valverde DA, Savio MC, et al
    Population-based Real-World Adoption of Advanced Therapies for Ulcerative Colitis in Brazil: Trends and Regional Differences from a Nationwide Public Healthcare Database.
    Gastroenterol Hepatol. 2026 Apr 9:502762. doi: 10.1016/j.gastrohep.2026.502762.
    PubMed         Abstract available
    
    

    
    Gastroenterology

20. FAN Q
    Unraveling the Functional Heterogeneity of Calprotectin Quaternary Structures in Inflammatory Bowel Disease.
    Gastroenterology. 2026 Apr 13:S0016-5085(26)00354.
    PubMed        
    
    

    
    Inflamm Bowel Dis

21. COSTA C, Estevinho MM
    Silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis.
    Inflamm Bowel Dis. 2026 Apr 10:izag063. doi: 10.1093.
    PubMed        
    
    
22. LE COSQUER G, Gilletta C, Kochar B, Ananthakrishnan AN, et al
    Frailty in inflammatory bowel disease: a missing link in personalized care for the aging IBD population.
    Inflamm Bowel Dis. 2026 Apr 11:izag031. doi: 10.1093.
    PubMed         Abstract available
    
    
23. MOHAMEDRASHED M, Yogakanthi S, Chauhan A, Lucas S, et al
    Skin-deep connections: likelihood of skin-scarring history in patients with stricturing/penetrating Crohn disease compared with patients with nonstricturing/nonpenetrating disease and non-inflammatory bowel disease controls.
    Inflamm Bowel Dis. 2026 Apr 13:izag058. doi: 10.1093.
    PubMed         Abstract available
    
    
24. CHIN S, Demase K, Corte C, Wong D, et al
    Quality of healthcare delivery in inflammatory bowel disease pregnancy: a scoping review.
    Inflamm Bowel Dis. 2026 Apr 15:izag064. doi: 10.1093.
    PubMed         Abstract available
    
    
25. CLEMOW DB
    Response to: The Long Game in Ulcerative Colitis: Mirikizumab's Four-Year Outcomes.
    Inflamm Bowel Dis. 2026 Apr 16:izag065. doi: 10.1093.
    PubMed        
    
    
26. BRIGGS KC, Tam A, Chaaban L, Luo A, et al
    Ustekinumab resistance in individuals with ulcerative colitis is associated with an alteration of a subset of proinflammatory mucosal regulatory T cells.
    Inflamm Bowel Dis. 2026 Apr 15:izag059. doi: 10.1093.
    PubMed         Abstract available
    
    
27. RAHMAN S, Xu B, Farah M, Kwok A, et al
    Longitudinal TCR repertoires in ulcerative colitis patients show features distinguishing disease states.
    Inflamm Bowel Dis. 2026 Apr 15:izag039. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

28. CHOCHINOV S, Dolovich C, Ly G, Oketola A, et al
    A Population-Based Assessment of Physical Activity and Exercise in Persons With IBD.
    J Clin Gastroenterol. 2026;60:432-441.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

29. EL-HUSSUNA A, Pellino G, Soriano A, Sahnan K, et al
    Results of the Ninth Scientific Workshop of the European Crohn's and Colitis Organisation (ECCO): artificial intelligence in IBD surgery-opportunities and limitations.
    J Crohns Colitis. 2026;20:jjaf135.
    PubMed         Abstract available
    
    
30. NOOR NM, Daperno M, de Laffolie J, Mookhoek A, et al
    Results of the Ninth Scientific Workshop of the European Crohn's and Colitis Organisation (ECCO): artificial intelligence in IBD: regulatory and methodological considerations.
    J Crohns Colitis. 2026;20:jjaf136.
    PubMed         Abstract available
    
    
31. KOPYLOV U, Verstockt B, Marigorta UM, Noviello D, et al
    Results of the Ninth Scientific Workshop of the European Crohn's and Colitis Organisation (ECCO): Artificial Intelligence in medical management and precision medicine.
    J Crohns Colitis. 2026;20:jjaf134.
    PubMed         Abstract available
    
    
32. MOOKHOEK A, Sinonquel P, Allocca M, Carter D, et al
    Results of the Ninth Scientific Workshop of the European Crohn's and Colitis Organisation (ECCO): artificial intelligence in endoscopy, radiology, and histology in inflammatory bowel disease diagnostics.
    J Crohns Colitis. 2026;20:jjaf133.
    PubMed         Abstract available
    
    
33. 
    Correction to: DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study.
    J Crohns Colitis. 2026;20:jjag042.
    PubMed        
    
    
34. SIMPSON AN, Sutradhar R, Benchimol EI, Chan WC, et al
    Assessing the impact of delivery method on severe maternal morbidity among individuals with inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2026;20:jjag014.
    PubMed         Abstract available
    
    
35. VAN KRUININGEN HJ, Colombel JF, Tonelli P
    Crohn's disease is an obstructive lymphangitis.
    J Crohns Colitis. 2026;20:jjag041.
    PubMed         Abstract available
    
    
36. MAHDY AKH, ElAbd H, Prinzensteiner M, Jebens H, et al
    Mapping adaptive immune responses toward fungal antigens in inflammatory bowel disease using T cell repertoire sequencing and phage-immunoprecipitation sequencing.
    J Crohns Colitis. 2026;20:jjag015.
    PubMed         Abstract available
    
    
37. NARDONE OM, D'Amico F, Calabrese G, Parigi TL, et al
    Risk of avoidant/restrictive food intake disorders in patients with inflammatory bowel disease: a matched cross-sectional case-control study.
    J Crohns Colitis. 2026;20:jjag033.
    PubMed         Abstract available
    
    
38. RAINE T, Lewis JD, Parkes GC, Long MD, et al
    Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization.
    J Crohns Colitis. 2026;20:jjag040.
    PubMed         Abstract available
    
    
39. 
    Correction to: Association between inflammatory bowel disease, current therapies, and cardiovascular events: a review and meta-analysis of data from 2.2 million individuals.
    J Crohns Colitis. 2026;20:jjaf128.
    PubMed        
    
    
40. VOS JMBW, Teichert C, De Voogd FAE, Pruijt MJ, et al
    The predictive value of intestinal ultrasound for treatment response in inflammatory bowel disease: a systematic review and pooled data analysis.
    J Crohns Colitis. 2026;20:jjag017.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

41. PU T, Feng R, Wang C, Zhao Y, et al
    Correction: METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-kappaB pathway.
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02398.
    PubMed        
    
    
42. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
    Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02399.
    PubMed        
    
    

    
    Minerva Gastroenterol (Torino)

43. BONGIOLO AM, Machado MJ, Lazarotto BA, Menegassi VS, et al
    Serum creatinine to cystatin C ratio as a predictor of muscle mass in patients with inflammatory bowel disease.
    Minerva Gastroenterol (Torino). 2026 Apr 17. doi: 10.23736/S2724-5985.26.04082.
    PubMed        
    
    

    
    PLoS One

44. BYRON C, Cornally N, Burton A, Lehane E, et al
    Psychological help-seeking behaviours amongst those living with Inflammatory Bowel Disease; A cross-sectional, descriptive, correlational study.
    PLoS One. 2026;21:e0346243.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum